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Deficits in ambulatory function progress at heterogeneous rates among individuals with
Duchenne muscular dystrophy (DMD). The resulting inherent variability in ambulatory out-
comes has complicated the design of drug efficacy trials and clouded the interpretation of
trial results. We developed a prediction model for 1-year change in the six minute walk dis-
tance (6MWD) among DMD patients, and compared its predictive value to that of com-
monly used prognostic factors (age, baseline 6MWD, and steroid use).
Methods
Natural history data were collected from DMD patients at routine follow up visits approxi-
mately every 6 months over the course of 2–5 years. Assessments included ambulatory
function and steroid use. The annualized change in 6MWD (Δ6MWD) was studied between
all pairs of visits separated by 8–16 months. Prediction models were developed using multi-
variable regression for repeated measures, and evaluated using cross-validation.
Results
Among n = 191 follow-up intervals (n = 39 boys), mean starting age was 9.4 years, mean
starting 6MWD was 351.8 meters, and 75% had received steroids for at least one year.
Over the subsequent 8–16 months, mean Δ6MWD was -37.0 meters with a standard devia-
tion (SD) of 93.7 meters. Predictions based on a composite of age, baseline 6MWD, and
steroid use explained 28% of variation in Δ6MWD (R2 = 0.28, residual SD = 79.4 meters). A
broadened prognostic model, adding timed 10-meter walk/run, 4-stair climb, and rise from
supine, as well as height and weight, significantly improved prediction, explaining 59% of
variation in Δ6MWD after cross-validation (R2 = 0.59, residual SD = 59.7 meters).
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Conclusions
A prognostic model incorporating timed function tests significantly improved prediction of 1-
year changes in 6MWD. Explained variation was more than doubled compared to predic-
tions based only on age, baseline 6MWD, and steroid use. There is significant potential for
composite prognostic models to inform DMD clinical trials and clinical practice.
Introduction
Approximately one in every 3,600 live male births is affected by Duchennemuscular dystrophy
(DMD), an inherited, X-linked disease caused by mutations to the gene encoding dystrophin
[1, 2]. Limitations in ambulatory function are among the earliest signs of the disease, and are
progressive. Patients initially develop muscle strength and ambulatory ability during their early
childhoodyears, but face increasing deficits relative to normal function as they age, and eventu-
ally experience accelerating declines. Loss of independent ambulation usually occurs by the
middle teens. Cardiac and pulmonary function are also impacted, contributing to a median
survival of approximately 25 years [3, 4]
Significant drug development efforts in DMD have been directed towards slowing the rate
of decline in ambulatory function [5–8]. The primary ambulatory outcome measure in recent
clinical trials has been the distance walked in six minutes (6MWD). To date, however, clinical
trials have been complicated by high levels of 6MWD variability. Within a 48-week trial period,
for example, changes in 6MWD among individual patients have spanned the full range from
improvement to complete loss of function [5]. There is also the potential for sub-maximal per-
formance of the 6MWD test to occur at baseline or at follow-up assessments. This variability
has confounded the accurate measurement of treatment effects, despite efforts to homogenize
trial enrollment based on age and baseline 6MWD. Natural history studies have corroborated
the levels of 6MWD variation observed in clinical trials [9]. Importantly, variability in 6MWD
across DMD patients is attributable primarily to biological variation in rates of progression.
Although 6MWD is effort based, and can be influenced by motivation, test-retest reliability is
high, with correlations exceeding 0.9 [10]. An improved understanding of the factors associ-
ated with biological variation in rates of 6MWD progression will be important for continued
design of clinical trials and measurement of drug effects in DMD.
To this end, prognostic factors for changes in 6MWD have been studied in DMD. Age and
baseline 6MWD, in particular, have been associated with rates of 6MWD progression [9]. Ste-
roid use has also been associated with preservation of ambulatory function in clinical trials and
in retrospective analyses of long-term observational data [11]. As such, these three factors: age,
baseline 6MWD and steroid use, have constituted the conventional patient characteristics used
in the design of DMD clinical trials measuring drug effects on 6MWD. Inclusion criteria, strati-
fied randomization procedures and subgroup pre-specifications, for example, have been based
primarily on these three characteristics [2, 8]. Despite these efforts, significant levels of unex-
plained variability in 6MWD outcomes have persisted, with standard deviations for changes in
6MWD typically exceeding twice the size of the treatment effect that trials are designed to
detect. This has complicated the interpretation of drug effects across multiple studies [12].
Beyond age, baseline 6MWD and steroid use, a number of functionalmeasures have been
individually or anecdotally associated with changes in 6MWD [10, 13, 14]. Multiple timed func-
tions tests, in particular, are routinely measured in clinical practice and in clinical trials. This
wealth of readily available functionalmeasures presents potential opportunities to improve
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prognosis. In particular, combining multiple measures into a composite score might improve
prognostic accuracy in DMD beyond that already provided by age, baseline 6MWD and steroid
use [15]. Composite prognostic scores have been useful for clinical trial design and clinical prac-
tice across multiple other therapeutic areas [16–18]. In drug efficacy trials, prognostic scores
have been incorporated into inclusion criteria and stratification criteria to manage variability
and reduce sample size requirements [18–20]. Prognostic scores have also been used to define
patient populations that benefit from treatment [21]. Comparisons of treated patients to natural
history controls have used prognostic scores to define efficientmatching criteria, particularly for
small sample sizes [8, 22, 23]. As DMD is a rare disease with rates of progression that are highly
heterogeneous compared to the effect sizes hypothesized for recently studied drug treatments,
improved prognosis—i.e., explaining heterogeneity in disease progression—could significantly
improve clinical trial design and analyses of drug efficacy.
With these ultimate aims in mind, we evaluated whether a combination of multiple, easily
measured patient characteristics could be used to improve 1-year prognosis for changes in
6MWD.
Study Design and Methods
Patients
Natural history data were collected from boys aged 4.4 years or older diagnosedwith DMD,
monitored in routine clinical practice at the Universitaire Ziekenhuizen (UZ) Leuven pediatric
neurology clinic in Leuven, Belgium.Assessments of 6MWD occurred approximately every 6
months, and included concurrent assessments of height, weight, steroid use and timed function
tests. Dystrophin genotypes were also recorded. Data collection for the present natural history
study spanned October 2008 to November 2015, and was truncated for patients entering clini-
cal trials.
To be included in the present analysis, boys were required to have at least one visit with
6MWD> 0 and at least one additional follow-up assessment of 6MWD. Changes in 6MWD
were then studied for all pairs of 6MWD assessments separated by approximately one year. In
particular, the study included all pairs of 6MWD assessments meeting the following criteria: 1)
6MWD> 0 at the first visit in the pair (defined as the baseline visit), 2) at least one subsequent
6MWD assessment after 8–16 months, and 3) all baselinemeasures non-missing. If a patient
had multiple pairs of visits meeting the above criteria, all such pairs were included in the analy-
ses (Fig 1).
Baselinemeasures included age, height, weight, timed rise from supine, timed 10 meter
walk/run, timed 4 stair climb, 6MWD, and steroid use history. Timed function tests and all
assessments were performed by trained clinical staff at UZ Leuven. Dystrophin genotypes were
also assessed, and were classified in the present study as deletions, duplications, point muta-
tions, or other alterations. Previous analyses of this cohort, based on an earlier data cut, have
been published [24].
This study was approved by the Ethics Committee of the University Hospitals Leuven, and
was conducted according to the Declaration of Helsinki. Written consent was obtained from
the parents of all boys to report their clinical assessment data anonymously in this observa-
tional study.
Statistical methods
Baseline characteristics were describedusing means and standard deviations for continuous
measures; counts and percentages were used for categorical measures. The primary outcome
measure, annualized change in 6MWD (Δ6MWD), was defined for each approximate 1-year
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interval (8–16 months) as the absolute change in 6MWD between assessments divided by the
corresponding number of elapsed years. Pearson correlations were studied betweenΔ6MWD
and each baseline characteristic, and for each pair of baseline characteristics.
Multivariable linear regressionmodels were used to study associations betweenΔ6MWD
and baseline characteristics. An initial model (Model 1) included only the conventional prog-
nostic factors: age, baseline 6MWD and steroid (dichotomized as duration of use greater than 1
year at the time of the baseline visit). A second, broader, model (Model 2) included the afore-
mentioned predictors in addition to weight, height and the timed function tests (TFTs). TFT
results were included in the model as separate effects for the ability to complete the test (as a
binary yes/nomeasure) and the time to completion (as a continuous measure set to 0 among
patients who could not complete the test). A third model assessed the addition of genotypic
class to the multivariable regression inModel 2. Sensitivity analyses explored the effects of add-
ing and removing specific variables to Models 1 and 2. Repeatedmeasures were accommodated
in all models using generalized estimating equations with an exchangeable covariance structure.
The predictive performance of these models was measured as the distance between observed
and predicted values of Δ6MWD. In particular, the root mean squared error (RMSE) was com-
puted as the standard deviation of differences between observed and predictedΔ6MWD. The
R2 value was used to measure the proportion of variance in Δ6MWD explained by the model.
Descriptive analyses of baseline characteristics and outcomes were also conducted for patients
stratified by quartiles of predictedΔ6MWD. These analyses were pre-specified in a Statistical
Analysis Plan developedwithin the TAP Collaboration.
To further assess the predictive performance and robustness of the broad multivariable model
(Model 2), a cross-validation approach was applied. The model was fit to 80% of the patients
(the training set: 31 patients and, on average, 153 follow-up intervals) and used to generate pre-
dictions for the remaining 20% (evaluation set: 8 patients and, on average, 38 follow-up inter-
vals). This process was repeated for 200 random splits of the data, and RMSE results were
averaged across the 200 evaluation samples. To obtain a 95% confidence interval (CI) for RMSE
a bootstrapping procedure was used to resample, with replacement, from the 39 patients. For
each of 1000 bootstrap iterations, a cross-validated estimate of RMSE was generated. Confidence
limits were obtained from the 2.5th and 97.5th percentiles of the bootstrappedRMSE distribution.
Finally, to explore the contributions of different baseline characteristics to the overall prog-
nostic value of the model, R2 values were estimated for a series of multivariable models
Fig 1. Study design. Changes in 6MWD were studied over approximate 1-year follow-up intervals (8–16
months). If a patient had multiple qualifying intervals, all such intervals were included in the analyses.
6MWD = six-minute walk distance.
doi:10.1371/journal.pone.0164684.g001
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obtained by separately adding each individual variable to Model 1 and by separately removing
each individual variable fromModel 2.
Results
Among a total of 54 patients with ambulatory 6MWD assessments, 39 met the inclusion crite-
ria and contributed a total of 191 approximate 1-year intervals of follow-up time to the analyses
(Fig 2). The average number of follow-up intervals was approximately 5 per patient. The
majority of the intervals were 12 ± 1 months in length.
Ages at baseline ranged from 4.4 to 15.7 years, with a mean of 9.4 years and a standard devi-
ation (SD) of 2.4 years. Mean 6MWD at baseline was 351.8 meters (m) with a SD of 80.1 m.
Steroids were being used at 86.4% (165/191) of baseline assessments; at most baseline assess-
ments, 74.9% (143/191), patients had been using steroids for at least 1 year. All 39 patients
eventually received steroids; 32 (82.1%) received deflazacort only, 5 (12.8%) received predni-
sone only, 1 (2.6%) switched from deflazacort to prednisone, and 1 (2.6%) switched from pred-
nisone to deflazacort. At assessments without 1 year of prior steroid use, the average age was
two years younger than at other visits (7.9 vs. 9.9 years). Among patients who could complete
the timed function tests, the median (interquartile-range) was 4.4 (3.1 to 6.6) seconds for rise
from supine (84.8% able to complete), 2.8 (2.0 to 4.8) seconds for the timed 4 stair climb
(94.2% able to complete), and 5.2 (4.2 to 6.8) seconds for the 10 meter walk/run (all patients
able to complete). The maximum observed times to completion were 24, 21, and 15 seconds,
respectively, for the rise from supine, 4 stair climb, and 10 meter walk/run tests.
The mean Δ6MWD, i.e. the mean annualized change from baseline, was—37.0 m with a SD
of 93.7 m (median = -16.3; range -343.7 to 131.4). Among the 191 study intervals, the ability to
complete the 6MWD test was lost in 24 cases (12.6%).
Fig 2. Observed vs. predicted changes in 6MWD. Predictions of Model 1 (a) and Model 2 (b). Each point represents one of the 191 follow-up
intervals. Red points indicate intervals during which the patient lost the ability to complete the 6MWD test. 6MWD = six-minute walk distance;
n = number; R2 = goodness of fit.
doi:10.1371/journal.pone.0164684.g002
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Pearson correlations were used to determine the strength of association between patient’s
baseline characteristics and subsequent 1 year changes in 6WMD (Table 1a). All studied base-
line characteristics had statistically significant associations with Δ6MWD. Moderately positive
associations were observedbetween declines in 6MWD and older age, lower baseline 6MWD
and longer duration of steroid use (magnitudes from 0.3 to 0.5; all statistically significant). Asso-
ciations were stronger for the timed rise from supine, the timed 4-stair climb, and the timed 10
meter walk/run; longer times to complete these tests at baseline were associated with greater
subsequent declines in 6MWD (magnitudes of correlation> 0.6; all statistically significant).
Greater height and weight were also significantly associated with greater declines in 6MWD.
Δ6MWDdid not differ significantly across genotypic classes (p = 0.554), with averages of -34.8,
-52.3, and -20.1 m, for patients with deletions, duplications, and point mutations, respectively.
Associations were also studied for each pair of potential prognostic factors. Significant cor-
relations were also observedamong all pairs of baseline characteristics (Table 1b). Age was pos-
itively associated with steroid duration, height and weight (correlation coefficients> 0.6), and
with the timed function tests (0.39 to 0.54). The negative association between age and 6MWD
was smaller in magnitude (0.25). All functional tests were strongly correlated with each other
(magnitudes 0.63 to 0.79).
When multiple baseline characteristics were combined to predict Δ6MWD, Model 1,
including only age, baseline 6MWD, and steroid use as predictors, explained 28% of the varia-
tion in Δ6MWD (Table 2a). Only age was a statistically significant predictor in this model,
with older age associated with a higher rate of decline in 6MWD. Unexplained variation in
Δ6MWD, as measured by the RMSE, was 79.4 m in this model (Fig 2a).
The broader multivariable predictionmodel (Model 2) based on the conventional predictors
plus height, weight, bodymass index (BMI), and timed function tests, performed significantly
better than Model 1 (Fig 2b). Model 2 accounted for almost 70% of the variation in 6MWD
changes (compared to 28% in Model 1), and reduced the unexplained variation to
RMSE = 52.3 m (compared to 79.4m inModel 1) (Table 2b). All baselinemeasures showed sig-
nificant associations with Δ6MWD except for age. After cross-validation was used to obtain a
Table 1. Correlations between each baseline characteristic and a) 1-year change in 6MWD and b) other baseline characteristics.
Baseline Characteristics
Age Steroids† Height Weight BMI 6MWD 10MWR Rise‡ 4SC‡
a) Associations with 1-year change in 6MWD
Δ6MWD -0.50 -0.45 -0.47 -0.40 -0.30 0.33 -0.62 -0.67 -0.65
b) Associations with other baseline characteristics
Age - 0.63 0.79 0.78 0.65 -0.25 0.54 0.46 0.39
Steroids† - - 0.30 0.34 0.38 -0.18 0.39 0.30 0.37
Height - - - 0.87 0.59 -0.13 0.46 0.49 0.37
Weight - - - - 0.90 -0.25 0.52 0.48 0.42
BMI - - - - - -0.28 0.46 0.36 0.36
6MWD - - - - - - -0.75 -0.63 -0.64
10MWR - - - - - - - 0.74 0.71
Rise‡ - - - - - - - - 0.79
Caption: All correlations were statistically significant (p<0.05). 6MWD = six-minute walk distance; Δ6MWD = annualized change in six-minute walk distance;
10MWR = ten-meter walk/run; BMI = body mass index; 4SC = four-stair climb; rise = rise from supine.
†Duration of use
‡For the purposes of these correlation analyses, patients who could not complete a test in < 30 seconds were assigned a value of 30 seconds.
doi:10.1371/journal.pone.0164684.t001
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conservative estimate of prognostic performance,Model 2 had an RMSE of 59.7 m (95% CI:
48.4 to 67.3) and a corresponding R2 of 0.59, and therefore continued to explain over twice the
variation in Δ6MWD than the model based only on conventional prognostic factors.
The addition of dystrophin genotype classes (point mutation, deletion, duplication, or
other) to Model 2 did not significantly improve the RMSE or R2 (51.7 m and 0.70, respectively),
and none of the genotypic classes exhibited a statistically significant association with Δ6MWD
after accounting for all of the other characteristics included in the model (data not shown). A
supplementary table (S1 Table) describes the performance of a series of multivariable models
obtained by adding or removing individual baseline characteristics from the analyses. The vari-
ables that reduced explained variation (R2) the most if removed fromModel 2 were baseline
6MWD and stair climb. The variables that contributed the most when added, separately, to
Model 1 were rise from supine and stair climb, followed closely by 10 meter walk/run.The vari-
ables that performed best in isolation were rise from supine and stair climb followed closely by
10 meter walk/run.
To further characterize the predictions based on Model 2, patients were stratified into four
groups based on quartiles of predictedΔ6MWD. ObservedΔ6MWD differed significantly
across these groups (Fig 3), and corresponded to the descriptors “fast decline,” “moderate
decline,” “stable,” and “improved.” Means ± SD for observedΔ6MWD across these quartiles
were -149.6 ± 92.9, -36.9 ± 48.0, -2.2 ± 50.7, and 41.2 ± 40.9 m respectively. The “fast decline”
quartile included all of the patients who had lost the ability to complete the 6MWD test during
the outcome period.Average baseline characteristics differed across quartiles: patients in the
“fast decline” group were the oldest, with a mean age of 11.3 years (Table 3b). The “fast decline”
group also had the highest rates of inability to complete the rise from supine and the 4 stair
climb, and had the longest average times to completion among patients who could complete
Table 2. Comparison of Multivariable models for annualized change in 6MWD.
a. Model 1 b. Model 2
6MWD, age, steroid predictors (RMSE = 79.4 m,
R2 = 0.28)
A broader set of predictors (RMSE = 52.3 m, R2 =
0.69)
Baseline characteristics Coefficient 95% CI Coefficient 95% CI
Intercept 135.8 (24.8, 246.7)* 812.5 (274.1, 1350.9)**
Age, years -21.1 (-30.9, -11.2)*** -2.4 (-7.9, 3.2)
Steroids 1 year -15.4 (-40.0, 9.2) -24.8 (-43.0, -6.6)**
6MWD, m 0.09 (-0.12, 0.29) -0.48 (-0.64, -0.32)***
Height, cm -6.8 (-11.3, -2.3)**
Weight, kg 12.9 (4.9, 21.0)**
BMI, kg/m2 -17.1 (-29.6, -4.6)**
Time to walk/run 10 m, s -10.0 (-17.3, -2.8)**
Able to rise from supine 60.4 (-12.6, 133.5)
Time to rise from supine, s† -4.2 (-7.4, -1.0)*
Able to climb 4 stairs 224.9 (139.9, 309.9)***
Time to climb 4 stairs, s† -12.9 (-20.7, -5.2)**
Caption: 6MWD = six-minute walk distance; BMI = body mass index; RMSE = root mean squared error; R2 = goodness of fit; s = seconds; m = meters;




†Set to 0 among patients unable to complete the test.
doi:10.1371/journal.pone.0164684.t002
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these tests. Patients aged older than 7 years were present in all quartiles. Patients with baseline
6MWD 350 meters were present in all quartiles, but were more than twice as prevalent in
the middle two quartiles (“moderate decline” and “stable”) compared with the extreme
quartiles.
Discussion
In this analysis of natural history data from a single center, timed function tests provided sig-
nificant prognostic value for 1-year changes in 6MWD. In particular, adding the timed 4-stair
climb, rise from supine, and 10 meter walk/run, along with height and weight, to a composite
prognostic model more than doubled the proportion of explained variation in Δ6MWD com-
pared to a model based only on conventional prognostic factors (age, baseline 6MWD, and ste-
roid use).
The composite prognostic model developed in this study builds on prior research in DMD.
Associations between changes in 6MWD and individual baseline factors have been previously
reported. For example, in a recent natural history study of patients with DMD, a baseline
6MWD of<350 m was associated with greater functional decline, loss of ambulation was only
observed in those with a baseline 6MWD<325 m, and just 2.3% of patients able to stand from
Fig 3. Observed changes in 6MWD stratified by baseline prediction quartiles. Solid horizontal lines
indicate medians and shaded boxes indicate interquartile ranges. Vertical lines encompass the ranges of
values in all groups except for the “stable” group, where the vertical lines cover 1.5 times the interquartile
range and exclude two outlying values (not shown) at -116.8 and 131.4 meters. 6MWD = six minute walk
distance; Δ6MWD = annualized change in six meter walk distance; m = meters.
doi:10.1371/journal.pone.0164684.g003
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supine lost ambulation [10]. The association between age and performance on the 6MWD test
has been described,with improvements occurringon average among boys younger than 7
years, and declines thereafter [25, 26]. The importance of potential composite prognostic mod-
els in DMD has been previously noted [15].
Table 3. Baseline Characteristics Stratified by Predicted Change in 6MWD.
a. Overall study sample b. Stratification by quartile of predicted Δ6MWD*
Baseline characteristics† Fast decline Moderate decline Stable Improved
(n = 191) (n = 48) (n = 48) (n = 47) (n = 48)
Age, years 9.4 (2.4) 11.3 (1.3) 10.3 (2.0) 8.8 (2.2) 7.3 (1.7)
Age category, years
< 5 2 (1.0) 0 (0.0) 1 (2.1) 0 (0.0) 1 (2.1)
(5, 7) 37 (19.4) 0 (0.0) 2 (4.2) 12 (25.5) 23 (47.9)
(7, 9) 44 (23.0) 2 (4.2) 7 (14.6) 15 (31.9) 20 (41.7)
(9, 12) 80 (41.9) 32 (66.7) 31 (64.6) 15 (31.9) 2 (4.2)
 12 28 (14.7) 14 (29.2) 7 (14.6) 5 (10.6) 2 (4.2)
Height, cm 123.3 (10.4) 131.5 (8.1) 127.2 (8.4) 119.8 (9.0) 114.5 (6.5)
Weight, kg 29.7 (9.4) 36.1 (8.3) 32.6 (8.5) 27.6 (8.9) 22.56 (5.6)
BMI, kg/m2 19.1 (3.4) 20.7 (3.8) 19.8 (2.9) 18.8 (3.5) 17.0 (2.3)
Genotype
Deletion 140 (73.3) 37 (77.1) 42 (87.5) 34 (72.3) 27 (56.2)
Duplication 36 (18.8) 9 (18.8) 5 (10.4) 8 (17.0) 14 (29.2)
Point mutation 15 (7.9) 2 (4.2) 1 (2.1) 5 (10.6) 7 (14.6)
Steroid duration, years 2.8 (2.0) 4.3 (1.8) 3.0 (2.0) 2.6 (1.9) 1.3 (1.2)
Steroid use category, months
< 1 26 (13.6) 4 (8.3) 5 (10.4) 4 (8.5) 13 (27.1)
(1, 6) 7 (3.7) 0 (0.0) 0 (0.0) 4 (8.5) 3 (6.2)
(6, 12) 15 (7.9) 0 (0.0) 3 (6.2) 5 (10.6) 7 (14.6)
(12, 24) 29 (15.2) 1 (2.1) 9 (18.8) 8 (17.0) 11 (22.9)
(24, 60) 78 (40.8) 23 (47.9) 20 (41.7) 21 (44.7) 14 (29.2)
 60 36 (18.8) 20 (41.7) 11 (22.9) 5 (10.6) 0 (0.0)
6MWD, m 351.8 (80.9) 283.8 (100.3) 398.0 (65.1) 386.0 (46.8) 339.8 (42.1)
6MWD category, m
< 150 2 (1.0) 2 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
(150, 250) 19 (9.9) 19 (39.6) 0 (0.0) 0 (0.0) 0 (0.0)
(250, 350) 61 (31.9) 14 (29.2) 10 (20.8) 7 (14.9) 30 (62.5)
(350, 450) 89 (46.6) 11 (22.9) 25 (52.1) 36 (76.6) 17 (35.4)
 450 20 (10.5) 2 (4.2) 13 (27.1) 4 (8.5) 1 (2.1)
Time to walk/run 10 m, s 5.9 (2.5) 8.9 (2.6) 5.5 (1.4) 4.8 (1.0) 4.4 (1.1)
Able to rise from supine 162 (84.8) 21 (43.8) 46 (95.8) 47 (100.0) 48 (100.0)
Time to rise from supine, s‡ 5.8 (3.9) 11.8 (5.8) 6.4 (3.0) 4.7 (2.3) 3.6 (1.3)
Able to climb 4 stairs 180 (94.2) 37 (77.1) 48 (100.0) 47 (100.0) 48 (100.0)
Time to climb 4 stairs, s‡ 3.9 (3.2) 8.2 (4.3) 3.4 (1.4) 2.7 (1.4) 2.2 (0.72)
Caption: 6MWD = six-minute walk distance; Δ6MWD = annualized change in six minute walk distance; n = number; s = seconds; m = meters.
*Thresholds for quartiles of predicted Δ6MWD (m) were < -73.5 for “fast decline,” [-73.5, -22.4) for “moderate decline”, [-22.4, 17.1) for “stable” and 17.1
for “improved,” and were based on Model 2.
†Means (standard deviations) are shown for continuous characteristics; counts (percentages) are shown for dichotomous and categorical characteristics.
Intervals represented as “(,)” indicate inclusive minimum thresholds and exclusive maximum thresholds.
‡Calculated among the subset of patients able to complete the test.
doi:10.1371/journal.pone.0164684.t003
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While the value of a prognostic model is most directly measured in terms of its predictive
accuracy, it is important to also consider the interpretation and clinical face validity of the esti-
mated associations driving the predictions. The estimated associations are conditional associa-
tions. That is, the estimated coefficients in Table 2 measure the association between a baseline
characteristic and Δ6MWDwhen all other baseline characteristics remain unchanged. To facil-
itate interpretation, we consider each baseline characteristic in turn.
• Age. BecauseDMD is a progressive disease, age has been widely used as prognostic factor. In
the present study, baseline age was strongly associated with Δ6MWD both individually and
in Model 1. However age did not make a significant contribution to the broader Model 2.
This indicates that, in the present study sample, the prognostic value of age for 1-year
Δ6MWDwas largely subsumedwithin that of height, weight, and the other functionalmea-
sures, which all had strong correlations with baseline age.
• 6MWD.When considered in isolation, baseline 6MWDwas positively associated with
Δ6MWD. However, the direction of this association reverses in Model 2. To help interpret
this change, a scatterplot of baseline 6MWD vs. Δ6MWD is included in S2 Fig, and shows that
the positive associationwas driven primarily by differences betweenboys who lose ambulation
(lower baseline 6MWD and greater loss) and those who do not (higher baseline 6MWD and a
mix of loss and gain). However, in S2 Fig it is apparent that within the group of boys who lose
ambulation the association is necessarily negative, and, separately, within the group of boys
who do not lose ambulation, the association between baseline 6MWD and Δ6MWD is weak
and not obviously positive.With this in mind, it is not surprising that adjustment for addi-
tional prognostic factors reverses the association. Statistically, this is an example of Simpson’s
Paradox [27]. In practical terms, it means that baseline 6MWD alone is not a reliable prognos-
tic factor: although a small fraction of patients with extremely low baseline 6MWD are almost
certain to lose ambulation in the next year, and a small fractionwith very high baseline
6MWD are almost certain to maintain ambulation, patients with intermediate baseline
6MWD have a mixture of subsequent rates of change that can be best resolved by other prog-
nostic factors. This is consistent with the presence of patients with baseline 6MWD 350 m
in all quartiles when patients are stratified by predicted change in Table 3b.
• Steroid use. There is substantial evidence that steroid use is protective in DMD [11, 28–31].
It may therefore be surprising that steroid use is associated with greater declines in 6MWD
inModel 2. The distinctionmust be drawn between a prognostic association (which is esti-
mated in Model 2) and a treatment effect (which is estimated in clinical trials of steroid use).
This distinction is common to all prognostic models. In the widely-used Framingham risk
score for cardiovascular disease, for example, use of antihypertensive medications is associ-
ated with increased risk, even after accounting for age, blood pressure, lipids and other fac-
tors [32]. The distinction is due to non-equivalence of correlation and causation, the
potential for confounding factors, and, most importantly, the fact that Δ6MWD is not stud-
ied from the time of steroid initiation. Duration of steroid use is likely to be associated with
the time from first diagnosis, and the potential benefits of prior steroid use are already
reflected in the baseline functional status.
• Weight, height and BMI. Because BMI is already a composite of height and weight, and
because all of these measures are highly correlated with each other and with age, it was some-
what surprising that all three contributed statistically to Model 2. Due to the strong correla-
tions among these measures we should not read too much into their estimated individual
effects (it is not possible to significantly change one of these measures without changing the
others). One observation is that higher weight versus age and height can reflect either higher
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muscle mass (which should enable ambulation) or higher body fat (which might limit perfor-
mance on 6MWD), or some combination of the two. Our finding that height and weight,
and their combination into BMI, are all important prognostic factors motivates further inves-
tigation of body composition and prognosis in DMD. Measures of lean bodymass, in partic-
ular, would be informative for future analyses.
• Timed function tests.All three timed function tests, rise from supine, 10 meter walk/run,
and 4 stair climb, showed strong associations with Δ6MWD. Longer times to complete these
tests were associated with worse prognosis for 1-year Δ6MWD. In addition, inability to com-
plete the tests, particularly the 4-stair climb, had a profoundly negative association with
Δ6MWD prognosis [12]. As stated previously, the fact that these TFTs add significant prog-
nostic information beyond that provided by baseline 6MWD, age, and steroid use is the pri-
mary finding of this study. However, it is perhaps not surprising. Physicians who see many
DMD patients report developing a gestalt prognosis based largely on these measures, which
have a long history of use in neuromuscular assessment [12, 33]. The composite prognostic
score developed in Model 2 formalizes and quantifies this gestalt prognosis.
• Genotypic classes.The present study considered only broad classes of genotypes due to lim-
ited sample sizes. No significant associations were observedbetweenΔ6MWD and any of the
genotypic classes. Previous analyses of larger samples have identified associations between
mutations affecting specific dystrophin exons and rates of progression in DMD [34]. As with
the non-significance of age in Model 2, the effects of genotypic class on progression may
already be captured by the other baseline functionalmeasures.
Among all baseline characteristics considered in this study, which are most important for
prognosis? As illustrated by the discussion of baseline 6MWD above, the prognostic impor-
tance of a variable cannot be measured in isolation. Like players in a team sport, the contribu-
tion of each must be measured in the context of others. By assessing the performance of a series
of composite models, each obtained by adding and removing specific individual variables, it
could be inferred that rise from supine, stair climb, 10 meter walk/run, and baseline 6MWD
were the most important prognostic factors for Δ6MWD, among all of the factors considered
in the present study, and that the prognostic value of baseline 6MWDwas greatly enhanced
when considered in conjunction with the TFTs.
Although the prognostic model developed in this study already offers potential for significant
improvement over conventionally used prognostic factors (age, baseline 6MWD and steroid
use), it is important to ask whether prognosis could be even further improved with additional
baseline information. Magnetic resonance imagingmeasures of fat fraction and genetic modifi-
ers have been associated with ambulatory outcomes in DMD, and warrant significant interest as
prognostic factors [35, 36]. In addition, becausemultiple timed function tests were helpful for
prognosis in the present analysis, it is possible that additional functionalmeasures could bring
further improvement. Measures of upper limbmobility, components of the North Star Ambula-
tory assessment, muscle strength testing, and other measures all warrant investigation as prog-
nostic factors [37]. Potential associations between pulmonary and/or cardiac function and
future changes in ambulatory functionwarrant further study, especially among older boys.
Rates of decline in pulmonary function, in particular, have been previously associated with age
at loss of ambulation [38]. Furthermore, due in part to the limited sample size, we did not inves-
tigate interactions among the available predictors or non-linear associations that could poten-
tially help improve prognosis. In future investigations, it will be important to consider
incremental prognostic value, i.e., the increase in prognostic accuracywhen a factor is added to
an already established composite score, in addition to pairwise associations with outcomes.
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The prognostic model presented here is specific to the studied population and the 6MWD
outcome measure. The present study included boys aged 4.4 years or older who could perform
the 6MWD tests and the TFTs, and had time to manifest deficits in these measures. Prognosis
in younger boys may dependmore heavily on genetic factors, imaging-basedbiomarkers, and
age-appropriate measures of strength and function [39, 40]. The 6MWD outcome was also
studied over a 1-year time horizon, due to the relevance of this outcome period for clinical tri-
als. Prognostic factors could differ for longer-term changes in 6MWD, changes in other out-
comemeasures, or time to loss of ambulation over longer follow-up periods.
The principal limitations of this study are that natural history data were drawn from a single
center and that, despite having a large number of 1-year follow-up intervals (n = 191), the
number of individual patients studied was smaller (n = 39). Small sample sizes increase the risk
of overfitting, which can artificially inflate measures of predictive accuracy. The use of cross-
validation to obtain conservative estimates of prognostic performance, and to avoid inflation
due to overfitting, was an important step towards addressing the limited sample size and dem-
onstrating internal validity. Establishing external validity in separate data is an important
future step. Evaluations in new data should consider both the quantitative prognostic perfor-
mance of the model (i.e., RMSE and R2) and the reproducibility of the qualitative conclusions,
particularly the observedprognostic importance of TFTs. This distinction between quantitative
and qualitative reproducibility is important because, at the time of this study, the consistency
of TFT assessments across different centers and study settings is unclear (e.g., clinical practice
vs. clinical trials). The models developed in the present study used TFT results from a single
center with internally consistent measurement procedures, and used the number of seconds for
completion directly in the prognostic model. Transformations of TFTs (e.g., based on thresh-
olds or conversion to velocities) could potentially improve consistency across data sources by
reducing sensitivity to very long completion times, and should be further explored in the con-
text of prognostic models.When evaluating the model in new data sources it will be important
to consider the baseline comparability of the ranges of TFT measurements, and comparability
in methods of assessment. We have explored model fitting with common TFT transformations
in S2 Table to facilitate such comparison across databases.
A validated prognostic score is a useful tool for clinical trial design and interpretation.
Once the score is calculated for each patient, it provides, by construction, a single number for
each patient that has a stronger association with outcomes than any of its components. In
general, a composite prognostic score can make clinical trial inclusion/exclusion, stratified
randomization and matching to natural history control groups more practical and feasible
compared to direct use of the multiple underlying prognostic factors, especially with small
sample sizes. For example, it may be feasible to stratify randomization or match patients on
the basis of a prognostic score, but not separately on multiple prognostic factors. As a rough
approximation of how much value could be provided by the prognostic score describedhere,
if reproducible in separate data, a standard power analysis (S1 Fig) shows that reducing the
unexplained error in Δ6MWD from 80 m to 60 m can cut almost in half the sample size
requirements for detecting treatment effect sizes that have been targeted and observed in
recent clinical trials. Limiting a trial to patients with “moderate decline,” a group whose tra-
jectoriesmay be hypothesized to be the most modifiable within a 1-year period, could even
further reduce the unexplained variability and sample size requirements. Potential increases
in power, and smaller sample size requirements, could enable smaller and faster trials, and
help avoid ambiguity in drug efficacy assessments in DMD.
While the impetus for the present study was to inform the design and interpretation of clini-
cal trials, prognostic scores can also be valuable in clinical practice. For example, a validated
prognostic score could potentially inform benefit-risk assessments and could help patients and
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families plan for loss of ambulation. The broad potential value of prognostic scores for DMD
highlights the urgency for further evaluation of the score developed here.
Supporting Information
S1 Fig. Reductions in sample size requirements associatedwith reductions in standard
deviation of Δ6MWD. Legend:Δ6MWD= change in six-minute walk distance; m = meters.
(TIF)
S2 Fig. Scatterplot for baseline 6MWD vs. Δ6MWD. Legend: 6MWD = six-minute walk dis-
tance; Δ6MWD= change in six-minute walk distance; m = meters.
(TIF)
S1 Table. R2 values after adding or removing specific baseline characteristics.Caption: R2
values decreased slightly after adding certain variables; note that models were fit using general-
ized estimating equations which, since they account for within-patient correlation, do not nec-
essarily minimize the marginal sum of squared prediction errors. R2 = measure of goodness of
fit; 6MWD = six-minute walk distance; BMI = bodymass index.
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